Trial Profile
Urinary angiotensinogen (AGT) becomes a biomarker for the selection of optimal antihypertensive drugs
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Olmesartan medoxomil (Primary)
- Indications Hypertension
- Focus Biomarker; Pharmacodynamics
- 28 Jun 2013 New trial record